|
|
|
|
Direct Cost |
Indirect Cost |
|
1DP2GM140925-01 |
Predictive engineering of cellular transcriptional state |
SLOAN-KETTERING INST CAN RESEARCH |
NIGMS |
$1,500,000 |
$1,155,000 |
$2,655,000 |
1F31CA247463-01A1 |
Investigating the role of tumor-associated macrophages in glioblastoma multiforme |
SLOAN-KETTERING INST CAN RESEARCH |
NCI |
$45,520 |
|
$45,520 |
1F31CA254130-01 |
Defining the biological consequences of somatic mutations in high risk AML using integrative single cell approaches |
SLOAN-KETTERING INST CAN RESEARCH |
NCI |
$45,520 |
|
$45,520 |
1F31CA254335-01 |
3UTR-dependent regulation of the PTEN tumor suppressor gene |
SLOAN-KETTERING INST CAN RESEARCH |
NCI |
$45,520 |
|
$45,520 |
1F31HL147468-01A1 |
Uncovering the Role of Platelets in Anti-Aspergillus Immune Defense |
SLOAN-KETTERING INST CAN RESEARCH |
NHLBI |
$45,520 |
|
$45,520 |
1F32CA247320-01 |
Mechanisms of ATM activation by the MRN complex and DNA Double Strand Breaks |
SLOAN-KETTERING INST CAN RESEARCH |
NCI |
$64,926 |
|
$64,926 |
1F99CA253706-01 |
Development of senolytic CAR T cells as new therapeutic agents |
SLOAN-KETTERING INST CAN RESEARCH |
NCI |
$47,020 |
|
$47,020 |
1K08CA237731-01A1 |
Investigating altered T-cell metabolism during chronic antigen encounter |
SLOAN-KETTERING INST CAN RESEARCH |
NCI |
$243,550 |
$19,484 |
$263,034 |
1K08CA245192-01A1 |
Investigating a hierarchical model for PI3K activation and inhibition in breast cancer by double PIK3CA mutations in cis |
SLOAN-KETTERING INST CAN RESEARCH |
NCI |
$243,550 |
$19,484 |
$263,034 |
1K08CA245206-01 |
Exploring the combinatorial efficacy between chemotherapy and T cell checkpoint inhibition and the role of cellular senescence |
SLOAN-KETTERING INST CAN RESEARCH |
NCI |
$240,832 |
$19,267 |
$260,099 |
1K08CA245242-01 |
Dissecting the Roles and Requirements for RBM39 in Acute Myeloid Leukemia and Normal Hematopoiesis |
SLOAN-KETTERING INST CAN RESEARCH |
NCI |
$223,735 |
$17,899 |
$241,634 |
1K08CA248723-01 |
Assessment of Tim-4+ Pleural Macrophages as Negative Regulators of Anti-Tumor T Cell Immunity in Lung Cancer |
SLOAN-KETTERING INST CAN RESEARCH |
NCI |
$185,718 |
$14,857 |
$200,575 |
1K08CA248964-01 |
Local blockade of IL10R on innate immune cells to mediate both innate and adaptive anti-tumor immunity |
SLOAN-KETTERING INST CAN RESEARCH |
NCI |
$243,550 |
$19,484 |
$263,034 |
1K08CA252157-01 |
Multi-antigen-specific CAR T cells to treat acute myeloid leukemia |
SLOAN-KETTERING INST CAN RESEARCH |
NCI |
$243,550 |
$19,484 |
$263,034 |
1K08CA252640-01 |
Leveraging implementation science to accelerate adoption of shorter-course radiation for breast and prostate cancer |
SLOAN-KETTERING INST CAN RESEARCH |
NCI |
$243,549 |
$19,484 |
$263,033 |
1K99AI148598-01 |
Investigating the function of ZU5 domain-containing proteins as amplifiers of caspase activation |
SLOAN-KETTERING INST CAN RESEARCH |
NIAID |
$98,892 |
$7,911 |
$106,803 |
1K99CA241310-01A1 |
Psychological Responses to the Possibility of Dying: Decision-Making Implications for Advanced Cancer Patients |
SLOAN-KETTERING INST CAN RESEARCH |
NCI |
$122,531 |
$9,802 |
$132,333 |
1K99CA248460-01 |
Interrogating oncogene-dependency and mutation order in FLT3 mutant AML |
SLOAN-KETTERING INST CAN RESEARCH |
NCI |
$143,238 |
$11,459 |
$154,697 |
1K99CA248711-01 |
Characterizing the biological function and therapeutic potential of mitochondrial NADP(H) |
SLOAN-KETTERING INST CAN RESEARCH |
NCI |
$110,959 |
$8,877 |
$119,836 |
1P50CA247749-01 |
MSK SPORE in Genomic Instability in Breast Cancer |
SLOAN-KETTERING INST CAN RESEARCH |
NCI |
$1,330,924 |
$926,773 |
$2,257,697 |